Incyte Corp (INCY) Stock Price, Quote & News

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 498 6700

Website: www.incyte.com

Address:

1801 Augustine Cut-Off, Wilmington, United States

Nomorelies Jun. 24 at 2:37 PM

$INCY Sector rotation is ongoing! Love it! $LABU &$IBRX $VKTX $BBIO $ALKS

0 · Reply

dumb_money_wins_again Jun. 24 at 1:59 PM

$INCY meh I don't think this will hold. it'll tank back below 100 as usual

1 · Reply

Nomorelies Jun. 23 at 12:03 PM

$ALKS $INCY Hold.

0 · Reply

BillionerOfKing Jun. 22 at 9:56 PM

$INCY Current Stock Price: $103.71 Contracts to trade: $105.0 INCY Jul 17 2026 Call Entry: $2.25 Exit: $2.95 ROI: 31% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Nomorelies Jun. 22 at 6:17 PM

$INCY Upgrading a stock after the fact is so stupid! That’s like a weatherman predicting yesterday’s weather. Idiot!

0 · Reply

Nomorelies Jun. 22 at 4:20 PM

$IBRX My bios are mainly up today. Possibly some sector rotation. $LABU $BBIO $INCY $ALKS

0 · Reply

WallStJesus Jun. 22 at 11:05 AM

$INCY BMO Raises to Market Perform From Underperform; Raises Target Price to $94

0 · Reply

anachartanalyst Jun. 22 at 10:02 AM

$INCY https://anachart.com/wp-content/uploads/2026/06/1782122467_soc-img.jpg

0 · Reply

Srinivas111 Jun. 17 at 5:23 PM

$INCY $VRTX two biotechs must own

0 · Reply

Srinivas111 Jun. 17 at 11:06 AM

$INCY $VRTX time to move some money into these

0 · Reply

Incyte price target raised to $105 from $103 at Truist

2026-06-22T08:35:45.000Z - 3 days ago

Incyte upgraded to Market Perform from Underperform at BMO Capital

2026-06-19T11:10:35.000Z - 5 days ago

Incyte Japan announces approval of Minjuvi combination for DLBCL

$Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)$

Jun 19, 2026, 2:00 AM EDT - 6 days ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

2026-06-14T21:20:07.000Z - 10 days ago

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

MIRM

2026-06-14T21:15:33.000Z - 10 days ago

Incyte announces clinical data from two Phase 2 studies of INCA033989

2026-06-14T21:10:35.000Z - 10 days ago

Incyte announces results from Phase 3 frontMIND trial of tafasitamab

Jun 14, 2026, 4:35 PM EDT - 10 days ago

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

MIRM

Jun 13, 2026, 11:15 AM EDT - 11 days ago

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Jun 13, 2026, 6:00 AM EDT - 12 days ago

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Jun 9, 2026, 8:40 AM EDT - 15 days ago

Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T18:55:10.000Z - 16 days ago

Incyte price target raised to $107 from $90 at Oppenheimer

2026-06-08T18:00:44.000Z - 16 days ago

Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal

COAG

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Incyte Transcript: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Incyte Press release: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Incyte Slides: M&A announcement

Jun 8, 2026, 7:34 AM EDT - 16 days ago

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Jun 8, 2026, 7:07 AM EDT - 17 days ago

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

2026-06-08T11:06:31.000Z - 17 days ago

Incyte to acquire Vega Therapeutics for $1.25B

Jun 8, 2026, 7:00 AM EDT - 17 days ago

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Jun 7, 2026, 6:11 AM EDT - 18 days ago

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

2026-06-04T12:21:26.000Z - 20 days ago

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

MIRM

2026-05-31T13:30:07.000Z - 24 days ago

Incyte announces results from Phase 3 frontMIND trial on tafasitamab

May 30, 2026, 8:02 AM EDT - 25 days ago

Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate

May 30, 2026, 8:00 AM EDT - 25 days ago

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

May 27, 2026, 8:00 AM EDT - 4 weeks ago

Incyte Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 4 weeks ago

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-21T21:15:27.000Z - 4 weeks ago

Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound

2026-05-21T20:27:18.000Z - 4 weeks ago

Incyte initiated with a Market Perform at Bernstein

May 20, 2026, 12:10 PM EDT - 5 weeks ago

Inside Incyte's $120 Million AI For Drug Development Deal

2026-05-20T12:19:27.000Z - 5 weeks ago

Incyte, Genesis Molecular AI announce expansion of collaboration

May 20, 2026, 8:00 AM EDT - 5 weeks ago

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

May 19, 2026, 10:30 AM EDT - 5 weeks ago

Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-19T12:13:08.000Z - 5 weeks ago

Incyte, Edison Scientific announce strategic collaboration to employ Kosmos

May 19, 2026, 8:00 AM EDT - 5 weeks ago

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

May 13, 2026, 4:40 PM EDT - 6 weeks ago

Incyte Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 9:30 AM EDT - 6 weeks ago

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

2026-05-07T19:58:38.000Z - 6 weeks ago

Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial

May 7, 2026, 8:50 AM EDT - 6 weeks ago

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

May 6, 2026, 4:30 PM EDT - 7 weeks ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-04T13:41:32.000Z - 7 weeks ago

Incyte gets orphan designation for treatment of pancreatic cancer

2026-05-01T21:30:21.000Z - 7 weeks ago

Incyte announces FDA approval of Jakari XR

May 1, 2026, 5:28 PM EDT - 7 weeks ago

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Apr 29, 2026, 8:00 AM EDT - 2 months ago